BofA Securities Upgrades Pharvaris B.V. (PHVS) to Neutral 'on potential label expansion for angioedema treatment'
Tweet Send to a Friend
BofA Securities analyst Tazeen Ahmad upgraded Pharvaris B.V. (NASDAQ: PHVS) from Underperform to Neutral with a price target of $27.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
